|
|
|
|
Monthly Steroid Pulses Cut MS Relapses 38 Percent With Few Side Effects, Study Finds
Findings from a new study suggest that monthly pulses of the steroid drug added to interferon beta-1a may be the optimal sequence for clinicians seeking to avoid relapses in relapsing-remitting multiple sclerosis.SEATTLE...
|
|
|
Insight Into How Brain Stem Cells Develop Into Cells Which Repair Damaged Tissue
Insight Into How Brain Develop Into Cells Which Repair Damaged Tissue Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and Disease Information from...
|
|
|
New Safety Data Reported on Natalizumab for MS and PML Risk
Data from the manufacturer of natalizumab suggest that better monitoring and clinical vigilance for progressive multiple leukoencephalopathy (PML) has led to improved clinical outcomes for MS patients who develop PML.SEATTLE-The...
|
|
|
Brain stem cell discovery could lead to new therapies
They have found that a signalling pathway (called Wnt) in brain stem cells may be a critical key to developing therapies that would enable the restoration of damaged tissues.The joint research, funded by the National Multiple ...
|
|
|
Insight Into How Brain Stem Cells Develop Into Cells Which Repair Damaged Tissue
The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of...
|
|
|
Business in the Burbs: Acorda reaches agreement to cover foreign sales of MS drug
Acorda Therapeutics Inc., a Hawthorne-based biotech company, announced an agreement to develop, commercialize and gain regulatory clearances for its new multiple sclerosis drug in foreign markets with the assistance of another...
|
|
|
Biogen Idec, Acorda enter pact to develop & commercialize MS therapy Fampridine-SR in outside US markets
Biogen Idec and Acorda Therapeutics, Inc.announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside...
|
|
|
UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Ben
UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS).Preliminary interim efficacy analysis showed that patients enrolled in...
|
|
|
Brain stem cell discovery
Insight could lead to new therapies to repair damage caused by MS.Scientists have discovered a new mechanism in brain stem cells that controls how and when they develop into cells which repair damage in neurological diseases such as ...
|
|
|
Important Modulator Of Immune Cell Entry Into The Brain Discovered
Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells.A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The researchers showed...
|
|
|
Clues to brain cell development, genetics study
The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of...
|
|
|
New clue into how brain stem cells develop into cells which repair damaged tissue
Insight could lead to new therapies to repair damage caused by MS The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical...
|
|
|
New clue into how brain stem cells develop into cells which repair damaged tissue
The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of...
|
|
|
New Discovery Into How Brain Stem Cells Develop Into Cells Which Repair Damaged Tissue
The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of...
|
|
|
Deal Struck, Shares Stuck
Motley Fool Stock Advisor Since 2002, David and Tom Gardner have returned 29.22% while the S&P 500 returned -11.18%.Try Stock Advisor free for 30 days. Acorda Therapeutics (Nasdaq: ACOR) secured a decent upfront payment to...
|
|
|
Deal Struck, Shares Suck
Motley Fool Stock Advisor Since 2002, David and Tom Gardner have returned 29.26% while the S&P 500 returned -11.17%.Try Stock Advisor free for 30 days. Acorda Therapeutics (Nasdaq: ACOR) secured a decent upfront payment to...
|
|
|
Multiple Sclerosis: A New Theory for Why Repair of the BrainEURs Wiring Fails
Scientists have uncovered new evidence suggesting that damage to nerve cells in people with multiple sclerosis (MS) accumulates because the bodys natural mechanism for repairing the nerve coating called myelin stalls out.The...
|
|
|
UCB, Biogen discontinue phase II trial of CDP323 for relapsing multiple sclerosis
UCB and Biogen Idec announced the discontinuation of the phase-II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS).Preliminary interim efficacy analysis showed that patients enrolled in this...
|
|
|
Biogen Idec buys rights to MS pill
NEW YORK - Biogen Idec Inc., the worlds largest maker of drugs for multiple sclerosis, will pay as much as $510 million for rights to market Acorda Therapeutics Inc.s experimental MS pill outside the United States.Acorda will...
|
|
|
Scientists find new mechanism in brain stem cells
London (PTI): Scientists have discovered a new mechanism in brain stem cells that controls how and when they develop into cells which repair damage in neurological diseases such as multiple sclerosis (MS).The scientists have...
|
|
|
Hard To Treat Diseases (HTDS) Clinical Trial Update On Therapeutic Effects Of Combined Treatment With Ribaviri
Hard To Treat Diseases (HTDS) Chief Scientist with its Slavica BioChem subsidiary, Dr.Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the potential...
|
|
|
MS study offers theory for why repair of brain's wiring fails
Scientists have uncovered new evidence suggesting that damage to nerve cells in people with multiple sclerosis accumulates because the body's natural mechanism for repair of the nerve coating called 'myelin' stalls out.The...
|
|
|
MS study offers theory for why repair of brain's wiring fails
Scientists have uncovered new evidence suggesting that damage to nerve cells in people with multiple sclerosis accumulates because the body's natural mechanism for repair of the nerve coating called 'myelin' stalls out.The...
|
|
|
Acorda Therapeutics shares fall on concerns Biogen partnership could cramp buyout possibility
NEW YORK (AP) Shares of Acorda Therapeutics Inc.fell Wednesday after the company gave overseas rights to the experimental multiple sclerosis drug Fampridine-SR, though investors have been hoping for a buyout, according to a...
|
|
|
UCB Group (UCBJF.PK) and Biogen Idec, Inc. (Massachusetts) (BIIB) Discontinue Phase II Clinical Trial of CDP32
Brussels (Belgium) -- UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS).Preliminary interim efficacy analysis showed that...
|
